TuHURA Biosciences Announces Three Presentations at the 68th American Society of Hematology Annual Meeting and Exposition

On November 4, 2026 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, reported that it would present three posters on its research on the role of the Delta Opioid Receptor (DOR) in controlling the immunosuppressive capabilities of Myeloid-Derived Suppressor Cells (MDSCs) at the upcoming 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting and Exposition taking place on December 12-15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We continue to be impressed by uncovering the central role the DOR plays in proliferation, recruitment and immune suppressing capabilities across MDSCs, T regs and M2 macrophages, the 3 most important naturally occurring immune suppressing cells in the body. These immune suppressing cells are an important mechanism for the body to calm chronic inflammation, but when highjacked in the setting of cancer, they are known to be culprits in resistance to and failure of cancer immunotherapy," said Dr. James Bianco, President and Chief Executive Officer of TuHURA Biosciences. "In addition to providing information critical to multiple patent submissions, the data underscore the breadth of the potential therapeutic applications for DOR technology in the development of a first new class of non-tumor targeting, immune modulating ADCs."

Poster Presentation Details:

Abstract Number: 4725
Title: Inhibition of the delta opioid receptor (DOR) on myeloid-derived suppressor cells (MDSCs) significantly reduces Cxcl10, Saa3 and Acod1 gene expression, representing a single target to modulate MDSC proliferation, migration and immune suppression.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

Abstract Number: 4721
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Taekyoung Kwak, Lead Scientist, Immunology and Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

Abstract Number: 4744
Title: Delta opioid receptor (DOR) inhibition drives both proenkephalin (PENK) gene expression and met-enkephalin (mENK) protein in tumor-derived myeloid-derived suppressor cells (tMDSC) and bone marrow-derived macrophage subtype 2 (BMDM2): Implications for modulation of immune suppression in cancer and autoimmune disease.
Presenter: Dr. Krit Ritthipichai, Director of Immunology
Session: 201. Granulocytes, Monocytes, and Macrophages: Poster III
Date and Time: Monday, December 14, 2026, 6:00pm to 8:00pm ET
Location: MCCNO – Hall F

(Press release, TuHURA Biosciences, NOV 4, 2026, View Source [SID1234674212])

Immunome to Present Initial First-in-Human Clinical Data for IM-1021 in Advanced B-Cell Lymphomas at ASH 2026

On November 4, 2026 Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, reported the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The poster will include initial results demonstrating responses across all dose levels evaluated in heavily pretreated patients with B-cell non-Hodgkin lymphoma (B-NHL). Among 19 response-evaluable patients with B-NHL, the objective response rate (ORR) was 53% (10/19), including five complete responses (CRs) and five partial responses (PRs). Among 11 response-evaluable patients with diffuse large B-cell lymphoma (DLBCL), the ORR was 64% (7/11), including three CRs and four PRs.

"At this interim read, we were encouraged to see clinical activity with IM-1021 in these heavily pretreated patients, including patients whose disease had progressed following T-cell redirecting therapies," said Bob Lechleider, M.D., Chief Medical Officer of Immunome. "These early results support our dose optimization efforts as we work to advance IM-1021 and further evaluate its potential for patients with B-cell lymphomas. The study is ongoing, and we look forward to presenting an updated dataset at ASH (Free ASH Whitepaper)."

As of the June 26, 2026, abstract data cutoff, 35 patients had received IM-1021, including 25 patients with B-NHL. Treatment-emergent adverse events (TEAEs) were reported in 92% of B-NHL patients. Grade ≥3 TEAEs occurred in 52% of B-NHL patients, of which the most common was neutropenia (44%). The patients with B-NHL had received a median of four prior lines of therapy, and prior T-cell redirecting therapy was common. Responses were observed across all dose levels tested. Dose optimization across multiple dosing regimens remains ongoing.

Presentation Details

Title: Initial results from first-in-human study of IM-1021, a ROR1-targeted antibody-drug conjugate with TOP1-inhibitor payload, in adults with advanced B-cell lymphomas

Presenter: Dr. Krish Patel (Sarah Cannon Research Institute)

Session: 629: Aggressive Lymphomas, Non-Cellular Immunotherapy including Bispecific Antibodies: Poster III

Publication Number: 5457

Location: MCCNO – Hall F

Date/Time: December 14, 2026, 6:00p.m. – 8:00p.m.

About the IM-1021-101 Trial

The Phase 1 IM-1021-101 study (ClinicalTrials.gov Identifier: NCT06823167) is an ongoing, first-in-human, open-label, multinational, multicenter dose-escalation and expansion study evaluating IM-1021 in patients with advanced B-cell lymphomas and advanced solid tumors. The study is designed to evaluate the safety and tolerability of IM-1021 and select recommended dose(s) for further study, as well as characterize preliminary antitumor activity and pharmacokinetics.

About IM-1021

IM-1021 is an investigational ROR1-targeted ADC currently being evaluated in a Phase 1 study in patients with advanced B-cell lymphomas. ROR1 is expressed in liquid and solid tumors but is largely absent in most mature tissues. IM-1021 incorporates an antibody designed to promote internalization and Immunome’s proprietary TOP1 inhibitor payload, HC74. Immunome designed IM-1021 to optimize ADC-mediated killing of ROR1-positive tumor cells. The company initiated enrollment in the Phase 1 study in the first quarter of 2025.

(Press release, Immunome, NOV 4, 2026, View Source [SID1234674228])

Secura Bio Announces Two Duvelisib Presentations on Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma at the 2026 American Society of Hematology Annual Meeting

On November 4, 2026 Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, reported two posters on duvelisib, the Company’s oral dual inhibitor of PI3K-δ and PI3K-γ, have been accepted for presentation at the upcoming 2026 American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting taking place December 12-15, 2026, in New Orleans, Louisiana.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A poster characterizing outcomes for peripheral T-cell lymphoma (PTCL) patients from the completed Phase 2 PRIMO study who achieved sufficient disease control with duvelisib to subsequently undergo stem cell transplant will be presented. Final results from the PRIMO study were published earlier this year in the Journal of Clinical Oncology.

A "Trials in Progress" poster detailing a new Phase 1 study for a novel topical formulation of duvelisib also will be presented. This is the first-ever clinical study evaluating a topical PI3K-δ/γ inhibitor in patients with early-stage Mycosis fungoides (MF), the most common subtype of cutaneous T-cell lymphoma (CTCL).

Presentation Details

Poster Number: 1834
Title: Duvelisib in Patients with Relapsed/Refractory Peripheral T-cell Lymphoma: Final Results from the Phase 2 PRIMO Trial: Outcomes in Patients who Proceeded to Stem Cell Transplant
Session Date: Saturday, December 12, 2026
Time: 5:30 pm – 6:30 pm EST
Location: MCCNO – Hall F
Presenter: Neha Mehta-Shah, M.D., Washington University School of Medicine, St. Louis, MO

Poster Number: 3619
Title: A Phase 1 dose-escalation study of topical duvelisib in patients with early-stage mycosis fungoides (MF)
Session Date: Sunday, December 13, 2026
Time: 6:00 pm – 8:00 pm EST
Location: MCCNO – Hall F
Presenter: Sima Rozati, M.D., Ph.D., Johns Hopkins University School of Medicine, Baltimore, MD

About Peripheral T-cell Lymphoma

Peripheral T-cell lymphoma (PTCL) is a rare, aggressive type of non-Hodgkin lymphoma that develops in mature white blood cells that circulate through the bloodstream and lymphatic system. PTCL accounts for between 10%-15% of all non-Hodgkin lymphomas and generally affects people aged 60 years and older. Although there are many different subtypes of PTCL, they often present in a similar way, with widespread, enlarged, typically painless lymph nodes in the neck, armpit, and/or groin. There are currently no well-established standards of care for patients with relapsed or refractory disease. ¹,²

About Cutaneous T-cell Lymphoma

Cutaneous T-cell lymphoma (CTCL) is a rare type of non-Hodgkin lymphoma that develops when white blood cells become abnormal and accumulate on the skin, presenting as painful, scaly patches, plaques or tumors that can spread across the body. Mycosis fungoides (MF) is the most common form of CTCL, affecting approximately 50%-60% of CTCL patients. Current treatment is generally broad-acting and not aimed at underlying biological causes of the disease.

About COPIKTRA (duvelisib)

COPIKTRA is an oral inhibitor of phosphoinositide 3-kinase (PI3K) and the first US approved dual inhibitor of PI3K-delta and PI3K-gamma pathways, two enzymes known to help support the growth and survival of malignant cells. PI3K signaling may lead to the proliferation of malignant cells and is thought to play a role in the formation and maintenance of a supportive tumor microenvironment. COPIKTRA is indicated in the United States for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after at least two prior lines of systemic therapy.³ COPIKTRA is also being developed for the treatment of peripheral T-cell lymphoma (PTCL), for which it has received Fast Track status in the United States and is being investigated in combination with other agents through investigator-sponsored studies. It is also being developed for the treatment of cutaneous t-cell lymphoma (CTCL). Treatment of T-cell lymphomas is a disease category for which COPIKTRA is not currently indicated. For more information on COPIKTRA, please visit www.COPIKTRA.com.

INDICATIONS AND USAGE

COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of systemic therapy.

Limitations of Use: COPIKTRA is not indicated or recommended for the treatment of any patients with CLL or SLL as initial or second line treatment due to an increased risk of treatment-related mortality.

IMPORTANT SAFETY INFORMATION

Treatment-related mortality occurred in 15% of COPIKTRA treated patients.
Fatal and/or serious infections occurred in 31% (4% fatal) of COPIKTRA-treated patients. Monitor for signs and symptoms of infection. Withhold COPIKTRA if infection is suspected.
Fatal and/or serious diarrhea or colitis occurred in 18% (<1% fatal) of COPIKTRA-treated patients. Monitor for the development of severe diarrhea or colitis. Withhold COPIKTRA.
Fatal and/or serious cutaneous reactions occurred in 5% (<1% fatal) of COPIKTRA-treated patients. Withhold COPIKTRA.
Fatal and/or serious pneumonitis occurred in 5% (<1% fatal) of COPIKTRA-treated patients. Monitor for pulmonary symptoms and interstitial infiltrates. Withhold COPIKTRA.
WARNINGS AND PRECAUTIONS

Treatment-related Mortality: In a randomized controlled trial in patients with relapsed or refractory CLL or SLL, treatment with COPIKTRA caused increased treatment-related mortality. With extended follow-up with a median of 63 months, treatment-related deaths occurred in 15% (23/158) of those patients in the overall population. In the indicated patient population, patients with relapsed or refractory CLL or SLL after at least two prior lines of systemic therapy. Treatment related deaths following treatment with COPIKTRA occurred in 14% (13/93) of patients. The most common cause of the treatment-related deaths were infections, which occurred in 9% and 11% of patients with relapsed or refractory CLL following at least one or two prior systemic therapies, respectively. COPIKTRA is not indicated and is not recommended for any patients in the initial or second-line treatment setting.

Infections: Serious, including fatal (18/442, 4%), infections occurred in 31% of patients receiving COPIKTRA. The most common serious infections were pneumonia, sepsis, and lower respiratory infections. Median time to onset of any grade infection was 3 months, with 75% of cases occurring within 6 months. Treat infections prior to initiation of COPIKTRA. Advise patients to report new or worsening signs and symptoms of infection. Cases of Pneumocystis jirovecii pneumonia (PJP) (1%) and cytomegalovirus (CMV) reactivation/infection (1%) occurred in patients taking COPIKTRA. Provide prophylaxis for PJP during treatment and following completion of treatment until the absolute CD4+ T cell count is greater than 200 cells/μL. Consider prophylactic antivirals during COPIKTRA treatment to prevent CMV infection, including CMV reactivation.

Diarrhea or Colitis: Serious, including fatal (1/442; 0.2%); diarrhea or colitis occurred in 18% of patients receiving COPIKTRA. Median time to onset of any grade diarrhea or colitis was 4 months, with 75% of cases occurring by 8 months. The median event duration was 0.5 months. Advise patients to report any new or worsening diarrhea.

Cutaneous Reactions: Serious, including fatal (2/442; 0.5%); cutaneous reactions occurred in 5% of patients receiving COPIKTRA. Fatal cases included drug reactions with eosinophilia and systemic symptoms (DRESS) and toxic epidermal necrolysis (TEN). Median time to onset of any grade cutaneous reaction was 3 months with a median event duration of 1 month. Presenting features for serious events were primarily described as pruritic, erythematous, or maculo-papular. Less common presenting features include exanthem, desquamation, erythroderma, skin exfoliation, keratinocyte necrosis, and papular rash. Advise patients to report new or worsening cutaneous reactions.

Pneumonitis: Serious, including fatal (1/442; 0.2%), pneumonitis without an apparent infectious cause occurred in 5% of patients receiving COPIKTRA. Median time to onset of any grade pneumonitis was 4 months with 75% of cases occurring within 9 months. The median event duration was 1 month with 75% of cases resolving by 2 months.

Hepatotoxicity: Grade 3 and 4 ALT and/or AST elevation developed in 8% and 2%, respectively, of patients receiving COPIKTRA (N=442). Two percent of patients had both an ALT or AST > 3 X ULN and total bilirubin > 2 X ULN. Median time to onset of any grade transaminase elevation was 2 months with a median event duration of 1 month. Monitor hepatic function during treatment with COPIKTRA.

Neutropenia: Grade 3 or 4 neutropenia occurred in 42% of patients receiving COPIKTRA (N=442), with Grade 4 neutropenia occurring in 24% of all patients. Median time to onset of grade ≥3 neutropenia was 2 months. Monitor neutrophil counts at least every 2 weeks for the first 2 months of COPIKTRA therapy, and at least weekly in patients with neutrophil counts < 1.0 Gi/L (Grade 3-4).

Embryo-Fetal Toxicity: COPIKTRA can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus and conduct pregnancy testing before initiating COPIKTRA treatment. Advise females of reproductive potential and males with female partners of reproductive potential to use effective contraception during treatment and for 1 month after the last dose.

ADVERSE REACTIONS

B-cell Malignancies Summary

Fatal adverse reactions within 30 days of the last dose occurred in 8% (36/442) of patients treated with COPIKTRA 25 mg BID. Serious adverse reactions were reported in 289 patients (65%). The most frequent serious adverse reactions that occurred were infection (31%), diarrhea or colitis (18%), pneumonia (17%), rash (5%), and pneumonitis (5%). The most common adverse reactions (reported in ≥20% of patients) were diarrhea or colitis, neutropenia, rash, fatigue, pyrexia, cough, nausea, upper respiratory infection, pneumonia, musculoskeletal pain, and anemia.

CLL/SLL

Fatal adverse reactions within 30 days of the last dose occurred in 12% (19/158) of patients treated with COPIKTRA and in 4% (7/155) of patients treated with ofatumumab. Serious adverse reactions were reported in 73% (115/158) of patients treated with COPIKTRA and most often involved infection (38%; 60/158) and diarrhea or colitis (23%; 36/158). The most common adverse reactions with COPIKTRA (reported in ≥20% of patients) were diarrhea or colitis, neutropenia, pyrexia, upper respiratory tract infection, pneumonia, rash, fatigue, nausea, anemia, and cough.

For specific information on the management of the adverse reactions above, please review Dose Modifications for Adverse Reactions within the full Prescribing Information.

DRUG INTERACTIONS

CYP3A4 Inducers: Coadministration with a strong or moderate CYP3A4 inducer may reduce COPIKTRA efficacy. Avoid coadministration with strong or moderate CYP3A4 inducers.

CYP3A4 Inhibitors: Coadministration with a strong CYP3A4 inhibitor may increase the risk of COPIKTRA toxicities. Reduce COPIKTRA dose when co-administered with a strong CYP3A4 inhibitor.

CYP3A4 Substrates: Coadministration of COPIKTRA with sensitive CYP3A4 substrates may increase the risk of toxicities of these drugs. Consider reducing the dose of the sensitive CYP3A4 substrate and monitoring signs of toxicities of the co-administered sensitive CYP3A4 substrate.

Please see the Prescribing Information, including Boxed Warning.

To report Adverse Reactions during use of COPIKTRA, contact Secura Bio, call 1-844-9Secura or 1-844-973-2872 and/or to FDA at www.fda.gov/medwatch or call 1-800-FDA-1088.

(Press release, Secura Bio, NOV 4, 2026, View Source [SID1234674243])

Asgard Therapeutics announces publication in Immunity demonstrating induction of cancer-fighting tertiary lymphoid structures across seven tumor types – and will present new AT-108 biomarker data at SITC 2026

On November 4, 2026 Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, reported the publication of a landmark study in the journal Immunity demonstrating that its proprietary cell reprogramming platform can reliably induce the formation of mature immunogenic tertiary lymphoid structures (imgTLSs) directly within tumors and across multiple tumor types.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

imgTLSs are strongly associated with improved responses to immunotherapy and better survival across many cancers. However, previous approaches have struggled to reliably induce the formation of imgTLS across diverse tumor microenvironments (TMEs).

Filipe Pereira, Co-founder and Head of Innovation at Asgard, and lead author of the paper, said: "These findings provide strong evidence that, using Asgard’s in vivo cell reprogramming technology alone, we can reliably induce mature immunogenic TLSs across multiple tumor types. Recent work has implicated natural cDC1s in the formation and maintenance of TLS, and our study shows that the cDC1-like cells generated by in vivo reprogramming recapitulate these functions, supporting the fidelity of our mechanism of action."

Cristiana Pires, Co-founder and Chief Executive Officer of Asgard Therapeutics, said: "Demonstrating reliable induction of mature, immunogenic TLSs is something many companies and institutions have been trying to achieve. Thus, these new results are an important validation of the potential of our platform to turn tumors into sites of productive anti-tumor immunity. Together with the data we are presenting at SITC (Free SITC Whitepaper), the findings further support our efforts to advance our lead asset AT-108 toward the clinic next year, where we believe it could have a transformative impact on cancer patients."

The study, titled "Inducing immunogenic lymphoid niches across cancers by tumor-to-dendritic cell reprogramming", demonstrated that reprogramming tumor cells into cDC1-like cells using Asgard’s proprietary in vivo technology induced imgTLS formation across murine models of seven tumor types – melanoma, colon, bladder, breast, lung, pancreatic and glioblastoma, including both subcutaneous and orthotopic models. This breadth of activity across multiple cancer types, all with different mutational burdens and TMEs, strongly supports a tumor-agnostic effect.

Induced immunogenic niches contained CD4+ and CD8+ T cells and B cells, with BCL6+ germinal centers driving class-switching and tumor-reactive antibodies. Moreover, B cells were required for both imgTLS formation and tumor control, linking the induced TME remodeling to anti-tumor function. Importantly, the same DC-LAMP+ cDC1-nucleated architecture was detected in human tumors, suggesting that cDC1 reprogramming engages a TLS program conserved in human tumors and supporting the clinical translation of in situ reprogramming to induce functional TLS in patients.

Furthermore, inducing imgTLSs by cell reprogramming led to dramatic increases in complete response rates, compared to anti-PD1 immune checkpoint blockade monotherapy, across all models tested, including 100% tumor regressions in colorectal and breast cancer models.

Researchers also found a statistically significant positive correlation between the presence of larger imgTLSs and better long-term tumor control, supporting the potential use of imgTLSs as a clinical response biomarker in oncology.

The study, a collaboration between Asgard Therapeutics, Lund University, Shanghai Cancer Centre and the University of Coimbra, can be found here: View Source

The mechanistic findings reported in Immunity are complemented by preclinical studies with Asgard’s lead candidate, AT-108. Following intratumoral administration, AT-108 induces dose-dependent immune remodeling, characterized by increased cytotoxic and activated T-cell populations, reduced immunosuppressive macrophages, and transcriptional signatures of B-cell and immunoglobulin-associated programs. Importantly, TME remodeling was reflected systemically in the blood, with measurable dose-dependent changes in circulating immune cells and transcriptional signatures, providing accessible pharmacodynamic biomarkers of AT-108 activity.

These AT-108 biomarker data will be presented in a poster at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper)’s (SITC) (Free SITC Whitepaper) 41st Annual Meeting, taking place 4-8 November 2026 in Phoenix, Arizona.

Details of the poster presentation are as follows:

Title: Preclinical characterization of local and systemic pharmacodynamic biomarkers of AT-108, a first-in-class in situ tumor-to-dendritic cell reprogramming agent

Abstract Number: 1055

Presenter: Emma Leire, Asgard Therapeutics

Date: Friday 6 November 2026

Location: Exhibition Halls 4-6

Times: 8:00 AM – 7:00 PM MT; Poster lunch session 12:15 PM – 1:45 PM MT; Poster reception: 5:30 PM – 7:00 PM MT

(Press release, Asgard Therapeutics, NOV 4, 2026, View Source [SID1234674158])

Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights

On November 4, 2026 Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, reported its financial results for the third quarter of 2026 and provided an update on recent business progress.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"The last few months have been truly transformational for Nuvectis," said Ron Bentsur, Chairman and Chief Executive Officer of Nuvectis. "The strategic in-licensing of ciprocopan (NXP100, our CFBi) and NXP200 (our paradox-breaker BRAF inhibitor) firmly establishes Nuvectis as a late-stage clinical development company with potential best-in-class assets. Our immediate priority is to advance ciprocopan toward a U.S. marketing application in PNH, as well as in additional indications. Our discussions with the FDA regarding the next steps for PNH are well underway, and we expect to provide an update before year-end. We plan to submit a U.S. IND for NXP100 by year-end. In parallel, we are building out our internal complement expertise to support a broad development program. Recently, we strengthened our team with the hiring of Dustin Little, M.D., a SVP Clinical Development and head of our Complement program. Dr. Little is a physician-scientist and board-certified nephrologist and brings the ideal combination of relevant industry experience, having worked in clinical development at AstraZeneca for a decade, and as a physician. We are excited to have him join the team."

Mr. Bentsur continued, "With its potential for a clear dosing convenience compared to injectable treatments and Fabhalta—the twice-daily oral CFBi—and supported by robust clinical data in PNH and IgAN as well as validating clinical data from the Fabhalta clinical trials, we believe ciprocopan has the potential to redefine the standard of care for patients in targeted settings."

"For NXP200, updated Phase 1b results in BRAF V600-mutated recurrent or progressive glioma were presented at the recent ESMO (Free ESMO Whitepaper) annual meeting. Single-agent NXP200 demonstrated durable responses, including complete responses, with activity also seen in patients previously treated with a BRAF inhibitor. The data are encouraging and underscore the potential of NXP200 to become a differentiated, best-in-class, second-generation, paradox-breaker BRAF inhibitor. We expect to submit a U.S. IND for NXP200 by year-end, and we look forward to providing additional NXP200 Phase 1b data from China, alongside a Phase 1b data update for NXP900, our SRC-Yes1 kinase inhibitor,in the coming months."

"We ended the quarter with approximately $140 million in cash, representing the strongest financial position in Nuvectis’ history," Mr. Bentsur concluded. "We expect this funding to support our operations into the second half of 2029, providing a runway that extends well beyond multiple potential value-creating clinical and regulatory milestones."

Recent Developments

· Completed in licensing of two potentially best-in-class drug candidates from Haisco Pharmaceutical Group and follow-on public offering anchored by leading healthcare investors.

Ciprocopan (NXP100)

· In July 2026, ciprocopan achieved its first global approval (in China), for the treatment of patients with PNH previously untreated with complement inhibitors. A second marketing application for ciprocopan in China is currently under review, for the treatment of PNH patients previously treated with anti C5 therapy, with approval expected in 1Q27; additional ongoing clinical trials for ciprocopan in China include a Phase 3 in IgAN and a Phase 2 study in lupus nephritis.

· Communications with the U.S. FDA about the potential of the clinical data package that led to the approval of ciprocopan in China for the treatment of PNH to support a marketing application for NXP100 in the U.S. are well underway and an update is expected by year-end; Nuvectis continues to explore additional opportunities and an IND submission, for an indication beyond PNH, is expected by year-end.

· Phase 3 results from a study conducted in China of a head-to-head comparison of NXP100 versus eculizumab (Soliris) in patients with PNH naïve to complement inhibition was presented at the (European Hematology Association 2026 conference), demonstrating a robust efficacy advantage of ciprocopan versus Soliris.

NXP200

· In September, NXP200 was granted Breakthrough Therapy Designation for the treatment of patients with BRAF V600-mutant, recurrent or progressive high-grade glioma by China’s Center for Drug Evaluation (CDE). In April, the project was selected as a pilot project under the "Pediatric Anti-tumor Drug R&D Encouragement Pilot Scheme (Starlight Program)" for the indication of pediatric BRAF V600-mutated recurrent or progressive glioma by CDE.

· In October, expanded NXP200 Phase 1b data in patients with recurrent or progressive BRAF V600-mutated gliomas were presented at the 2026 ESMO (Free ESMO Whitepaper) Congress. As of the May 4, 2026 cutoff, 27 efficacy-evaluable patients with recurrent or progressive BRAF V600 glioma were treated with NXP200 monotherapy, including 20 patients with high-grade glioma and 7 with low-grade glioma.

o Treatment with NXP200 resulted in an ORR of 40.0% in the high-grade glioma cohort, including 3 CRs (two confirmed and one preliminary) and 42.9% in the low-grade glioma cohort, including one confirmed CR. All response assessments were based on RANO 2.0 criteria. Notably, among the three patients previously treated with a BRAF inhibitor, two achieved a partial response and one had stable disease.

o Deep responses (>80% tumor burden reduction) were achieved in 87.5% of responders with high-grade glioma and 66.7% of responders with low-grade glioma. 81.5% of the patients in the study achieved a tumor reduction.

· A U.S. IND submission is expected by year-end.

· Updates from the ongoing Phase 1b study in China, including in additional tumor types, are expected in early 2027.

NXP900

· NXP900 Phase 1b clinical development continues to focus on combination opportunities:

o Non-small cell lung cancer (NSCLC): the clinical trials evaluating the combination of NXP900 plus osimertinib (Tagrisso) in patients with NSCLC EGFR+ and the combination with lorlatinib (Lorbrena) in patients with NSCLC ALK+ are ongoing. Update from Phase 1b expected during the first half of 2027.

o Pancreatic cancer: An investigator-sponsored trial to evaluate the combination of NXP900 plus the recently approved daraxonrasib in patients with pancreatic cancer is planned at two leading medical centers in the U.S.

Corporate Updates: Recent Hire Strenthens Our Clinical Development Team

Dustin Little, MD, joined Nuvectis as Senior Vice President, Head of the Complement program, in September 2026. Dr. Little is a physician-scientist and board-certified nephrologist with a decade of pharmaceutical industry experience driving drug development from asset acquisition through program design, regulatory submission and approval. From 2016-2026, Dr. Little worked at Astra Zeneca and most recently served as Global Clinical Head, Late Cardiovascular, Renal, and Metabolism (CVRM), providing clinical leadership for renal disease area strategy at AstraZeneca as well as multiple first-in-class/potential first-in-class treatments for people living with kidney, cardiovascular, or hematologic diseases. Dr. Little also represented AstraZeneca externally in regulatory interactions and on major industry, academic and drug development advisory bodies.

Dr. Little earned his doctorate degree from the University of Washington School of Medicine in 2007. Between 2007-2016 Dr. Little served in the US military during which time he completed his internal medicine residency at the Madigan Army Medical Center and nephrology fellowship at the Walter Reed National Medical Center. In 2013, Dr. Little deployed to Afghanistan as a squadron physician. Dr. Little continues to treat patients as a volunteer at a Washington, DC-area nephrology clinic.

Mr. Bentsur said, "We welcome Dustin to Nuvectis. Dustin has had an immediate impact on the NXP100 program including involvement in the FDA discussions for PNH, conducting prioritization assessments of other indications, protocol writing and interactions with top key opinion leaders. Dustin’s knowledge and understanding of the complement inhibition in nephrology and hematology diseases are exceptional and we look forward to harnessing his expertise as we set out to establish NXP100 as a potential best-in-class compound across several indications."

Dr. Little commented, "It’s exciting to join Nuvectis at such a transformative time. The company has built a strong foundation and NXP100, as a late-stage once-a-day oral CFBi, represents a unique opportunity for significant impact across several indications. Leveraging my industry experience and medical knowledge, I look forward to helping spearhead this program forward while utilizing the compelling NXP100 Chinese and other CFBi data as a roadmap for our development plans."

Third Quarter 2026 Financial Results

Cash and cash equivalents were $140.7 million as of September 30, 2026, compared to $31.6 million as of December 31, 2025. In July, the Company raised $115.0 million in gross proceeds in a follow-on offering and additional $39.5 million of cash was raised via the existing ATM of which $37.0 million placed with a single healthcare dedicated fund.

The Company’s net loss was $30.1 million for the three months ended September 30, 2026, compared to $7.5 million for the three months ended September 30, 2025, an increase in net loss of $22.6 million, which includes a one-time upfront payment associated with the NXP100 and NXP200 license agreement of $20.0 million, and $1.8 million in milestones associated with NXP900. Non-cash stock-based compensation was $2.4 million for the three months ended September 30, 2026, compared to $1.5 million for the three months ended September 30, 2025. Net of the up-front license payment, the one-time milestone associated with NXP900 and non-cash stock-based compensation, the net loss for the third quarter 2026 was $5.8 million.

Research and development expenses were $27.4 million for the three months ended September 30, 2026, compared to $5.8 million for the three months ended September 30, 2025, an increase of $21.6 million. The increase was primarily driven by the $20.0 million upfront payment for the NXP100 and NXP200 license agreement, $1.8 million in milestones associated with NXP900, a $1.2 million increase in employee compensation and benefits, $0.5 million increase in clinical trial expenses and a $0.1 million increase in manufacturing costs, partially offset by $2.0 million in license fees paid in 2025. Non-cash stock-based compensation was $1.5 million for the three months ended September 30, 2026, compared to $0.9 million for the three months ended September 30, 2025.

General and administrative expenses were $3.7 million for the three months ended September 30, 2026, compared to $2.0 million for the three months ended September 30, 2025, an increase of $1.7 million. The increase was primarily driven by a $1.2 million increase in professional and consulting services and a $0.4 million increase in employee compensation and benefits. Non-cash stock-based compensation was $0.9 million for the three months ended September 30, 2026, compared to $0.6 million for the three months ended September 30, 2025.

Finance income was $1.0 million for the three months ended September 30, 2026, and $0.3 million for the three months ended September 30, 2025.

Conference Call and Webcast Information:

Time: 8:00 AM ET

Date: Wednesday, November 4, 2026

Participant Dial-In (U.S.): 1-877-407-0752

Participant Dial-In (International): 1-201-389-0912

Conference ID: 13763643

Webcast Access: Please click here

(Press release, Nuvectis Pharma, NOV 4, 2026, View Source [SID1234674174])